Cipla USFDA approval: Albuterol inhaler boost 2026

What Cipla announced

Cipla Ltd said it has received final approval from the US Food and Drug Administration (USFDA) for its generic version of albuterol sulfate inhalation aerosol. The approval is for Cipla’s abbreviated new drug application (ANDA) for albuterol sulfate inhalation aerosol of strength 90 mcg per actuation, as disclosed in a regulatory filing. Cipla positioned the decision as a portfolio addition in a core therapy area where it already has a strong presence. The product is indicated for treatment or prevention of bronchospasm, which makes it relevant across common obstructive airway conditions. The development also drew immediate attention in the market, with reports noting the stock moved up on the day of the update.

The product and dosage details

Cipla’s approval covers albuterol sulfate inhalation aerosol at 90 mcg per actuation. The company stated the medicine is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged four years and older who have reversible obstructive airway disease. It is also indicated for the prevention of exercise-induced bronchospasm in patients aged four years and older. These indications place the product in a widely used rescue inhaler category within respiratory care. Cipla described the approval as an extension of its respiratory offerings in the US market.

AB-rated generic status and the reference brand

In its filing, Cipla said the product is the first AB-rated generic therapeutic equivalent of Ventolin HFA, marketed by GlaxoSmithKline. Separately, another portion of the provided material linked the approval to Proventil HFA Inhalation Aerosol, marketed by Merck & Co., and described Cipla’s product as the first AB-rated generic therapeutic equivalent of Proventil HFA. Across these references, the common point is final USFDA approval for an albuterol metered dose inhaler product. The AB-rating is relevant because it signals therapeutic equivalence for substitution at the pharmacy level, subject to local rules.

What Cipla’s management said

Cipla Managing Director and Global CEO Achin Gupta said the approval marks an important milestone and reflects the company’s scientific and regulatory capabilities in complex inhalation products. He added that lung health remains central to Cipla’s offerings and that the company aims to build a sustainable and differentiated portfolio for patients globally. In another report included in the provided material, Cipla MD and Global CEO Umang Vohra said the company will continue to build its portfolio of drug-device combinations in respiratory. The same report said Cipla is planning shipments in a staggered manner. These statements underscore that Cipla views inhalation products as a priority area in its US strategy.

How the approval fits Cipla’s US respiratory portfolio

Cipla said the approval enhances its US respiratory portfolio and reinforces its leadership in the albuterol inhalation category. The company also noted it has approved generics for both Ventolin HFA and Proventil HFA. That detail is important because it signals a portfolio approach within albuterol rather than a single-product entry. The update comes amid multiple USFDA-related developments referenced in the material, keeping investor focus on the pace of approvals and the company’s ability to execute in complex inhalation formats.

A second USFDA approval in focus: nintedanib

Cipla USA Inc., a wholly owned subsidiary of Cipla Limited, announced on April 3, 2026 that it received final USFDA approval for its ANDA for Nintedanib Capsules, 100 mg and 150 mg. The product is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). Cipla said its nintedanib capsules are the generic therapeutic equivalent of Ofev, marketed by Boehringer Ingelheim. The company stated it is set to launch the product on an immediate basis. It also said the product will be available through appropriate pharmacy distribution channels, including specialty distribution.

Market reaction and stock snapshot

Market reports cited that Cipla’s shares rose about 3% on the day of the albuterol approval update. A stock snapshot included in the provided material listed Cipla at ₹1,293.60, up 4.63%, with a 5-day change of +5.11% and a change since Jan 1 of -14.42%. While the percentage moves differ across sources and time stamps in the provided text, the direction described was positive following the approval headline. Investors typically track these updates because US approvals can expand addressable product baskets and create near-term execution milestones when a launch plan is stated.

Key facts table

Why this matters for investors and the sector

The albuterol approval is notable because it sits in a high-volume respiratory category where brand substitution dynamics can matter. Cipla also framed the approval as strengthening its US respiratory portfolio, suggesting it expects the category to remain strategically important. The nintedanib update adds a second, clearly stated commercial step, as Cipla USA communicated an immediate launch plan and outlined distribution through pharmacy and specialty channels. Together, these approvals keep attention on Cipla’s US pipeline execution, particularly in respiratory drug-device combinations where regulatory and technical thresholds can be higher than standard oral generics.

What to watch next

Cipla has communicated final USFDA approval for albuterol sulfate inhalation aerosol and has separately stated an immediate launch plan for nintedanib capsules. Investors will watch for further company updates on shipments and product availability, especially where the company has referenced staggered shipments. Future regulatory filings and launch communications from Cipla USA may provide additional clarity on rollout pace and channel availability. Any subsequent disclosures on additional respiratory ANDAs, approvals, or inspections would likely remain in focus given the recent cluster of USFDA-related developments cited in the material.